Posters

Comparative analysis of the implantation of aberration-free and aspheric IOL in patients after keratorefractive surgery

Poster Details

First Author: S.Anisimova RUSSIA

Co Author(s):    L. Zagrebelnaya   -                 

Abstract Details

Purpose:

To assess the quality of the optical system of the eye and quality of vision after phacoemulsification with implantation of the aberration-free IOL (Incise, Valeant) in patients underwent previously keratorefractive surgery.

Setting:

Moscow, Eye Center “East Sight Recovery”.

Methods:

34 eyes of 18 patients after keratorefractive surgery underwent femtosecond laser-assisted phacoemulsification. 14 patients underwent radial keratotomy 20-25 years ago, 4 patients were after Lasik. In I group ( 16 eyes) 8 patients received an aberration-free IOL Incise (Valeant). In II group (18 eyes) 10 patients received aspheric IOLs. Preoperative ophthalmic examination included corneal topography with Orbscan II and wavefront analysis with Zywave aberrometer ( Valeant). IOL calculation was performed with Barrett Universal II formula. Postoperatively, refractive outcomes, uncorrected and best corrected visual acuity were determined. Pre- and postoperatively wavefront aberrometry were studied to assess the quality of vision.

Results:

Follow-up period was 3-10 months. In both groups, best corrected visual acuity 0.8 and better was achieved in 80% with. Target refraction (+0,5 D) was achieved in 72 % cases. In 3 months the mean value of HOAs in the first group was 0,69 µm, total aberrations -1,05 µm. In the second group HOAs -1,08 µm, total aberrations -1,87 µm. The patients satisfaction was higher in Incise IOL group.

Conclusions:

No significant difference was found between IOLs in terms of visual acuity. Asheric IOL implantation in patients after keratorefractive surgery may increase total aberrations of the eye. The aberration-free IOL Incise has been shown lower level of HOAs and total aberrations and higher level of satisfaction in patients after keratorefractive surgery.

Financial Disclosure:

None